Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14397137 | 0.93 | CASR (0.65) | CASR | |
| SCHEMBL14397253 | 0.92 | CASR (0.64) | CASR | |
| SCHEMBL2970960 | 0.92 | CASR (0.63) | CASR | |
| SCHEMBL2976846 | 0.89 | CASR (0.80) | CASR | |
| SCHEMBL2503512 | 0.89 | CASR (0.77) | CASR | |
| SCHEMBL13136639 | 0.89 | CASR (0.82) | CASR | |
| SCHEMBL2497990 | 0.86 | CASR (0.78) | CASR | |
| SCHEMBL2980100 | 0.86 | CASR (1.00) | CASR | |
| SCHEMBL2501722 | 0.85 | CASR (0.85) | CASR | |
| SCHEMBL2497421 | 0.85 | CASR (0.78) | CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227889-A1 | Benzimidazole Derivatives | NOVARTIS AG (CH) | 2010-09-09 | — | — | US | claimed |
| EP-2004629-A2 | BENZIMIDAZOLE DERIVATIVES | Novartis AG (CH) | 2008-12-24 | — | — | EP | claimed |
| WO-2007112913-A2 | BENZIMIDAZOLE DERIVATIVES | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | claimed |
| US-20100227889-A1 | Benzimidazole Derivatives | NOVARTIS AG (CH) | 2010-09-09 | — | — | US | disclosed |
| US-20100227889-A1 | Benzimidazole Derivatives | NOVARTIS AG (CH) | 2010-09-09 | — | — | US | disclosed |
| US-20100227889-A1 | Benzimidazole Derivatives | NOVARTIS AG (CH) | 2010-09-09 | — | — | US | disclosed |
| EP-2124893-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A CALCILYTIC AGENT | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| EP-2004629-A2 | BENZIMIDAZOLE DERIVATIVES | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2008107390-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A CALCILYTIC AGENT | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | disclosed |
| EP-1964548-A1 | Pharmaceutical compositions comprising a calcilytic agent | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007112913-A2 | BENZIMIDAZOLE DERIVATIVES | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227889-A1 | Benzimidazole Derivatives | BMX, SOST, HDAC4 | CASR 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.